Brain Tumor Drugs Market Forecast Reveals Where Future Industry Value Will Be Created
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Brain Tumor Drugs Market Growth Potential: How Will Market Size Change Through 2030?
The market for brain tumor drugs has experienced robust expansion in recent years. Projected to rise from $4.03 billion in 2025 to $4.26 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 5.7%. Several factors have driven this historic period of growth, including a higher incidence of brain tumors, progress in chemotherapy agents, greater public awareness of symptom management, the creation of hormone-based treatments, and the launch of innovative anticonvulsant medications.
The market for brain tumor drugs is projected to experience robust expansion over the coming years. By 2030, it is anticipated to reach a value of $5.5 billion, driven by a compound annual growth rate (CAGR) of 6.6%. This forecasted growth is fueled by advancements in precision medicine, the incorporation of artificial intelligence into drug development, heightened oncology research and development efforts, rising healthcare spending, and a growing preference for targeted therapies. Key developments shaping this period include the emergence of personalized chemotherapy approaches, an increase in hormone therapy utilization, the introduction of sophisticated pain management medications, a greater reliance on anticonvulsants for symptom relief, and an expanding array of drugs in the brain tumor pipeline.
Download A Free Sample Report For Comprehensive Market Insights:
Brain Tumor Drugs Market Demand Drivers: What Is Fueling Industry Growth?
The rising number of individuals receiving chemotherapy is anticipated to drive the growth of brain tumor drugs in the coming period. Chemotherapy refers to a therapeutic approach where potent medicines are employed to attack and eliminate fast-dividing cells, including cancerous ones. As a fundamental treatment option for brain tumors, chemotherapy relies on the development and accessibility of effective drugs, which greatly influence treatment success rates. The effectiveness of chemotherapy is key to extending patient survival and enhancing their life quality, thereby steering market dynamics. For example, in July 2023, the Centers for Disease Control and Prevention, a US governmental agency, reported that over 1 million cancer patients in the United States undergo chemotherapy or radiation annually. Consequently, the growing number of patients undergoing chemotherapy is fueling expansion in the brain tumor drug market.
Brain Tumor Drugs Market Segment Analysis Highlighting Growth Areas
The brain tumor drugs market covered in this report is segmented –
1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users
3) By Mechanism of Action: Chemotherapy Agents, Targeted Therapy, Hormone Therapy
Subsegments:
1) By Temozolomide: Oral Formulation, Injectable Formulation
2) By Bevacizumab: Monoclonal Antibody Therapy, Combination Therapy With Chemotherapy
3) By Other Drugs: Carmustine, Lomustine, Etoposide, Irinotecan, Novantrone (Mitoxantrone)
Brain Tumor Drugs Market Innovation Trends: Which Developments Are Transforming The Industry?
Top companies in the brain tumor drugs sector are increasingly emphasizing innovations like targeted RAF kinase inhibitors to address the growing need for precision oncology therapies that focus on particular genetic changes in brain tumors, thus lowering overall toxicity and enhancing patient recovery. A RAF kinase inhibitor works by specifically hindering the activity of RAF proteins involved in the MAPK signaling cascade, which stops tumor cell growth; this method differs from conventional chemotherapy, which attacks all quickly dividing cells indiscriminately and frequently results in more extensive adverse effects throughout the body. As an example, in November 2025, Day One Biopharmaceuticals, a biotechnology firm based in the United States, introduced OJEMDA (tovorafenib), a groundbreaking treatment for children with relapsed or refractory low-grade gliomas that exhibit BRAF fusions or V600 mutations. Tovorafenib is a once-weekly, orally taken inhibitor capable of crossing the blood-brain barrier, precisely acting on mutated RAF proteins, giving strong penetration into the central nervous system and a mode of action customized to the tumor’s genetic root cause. Key characteristics of this drug include high targeting precision, less systemic harm relative to standard chemotherapy, and its appropriateness for pediatric use. This product marks a notable step forward in genetically driven therapy for childhood brain cancers.
Brain Tumor Drugs Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the brain tumor drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co. Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.
Access The Complete Brain Tumor Drugs Market Report:
Brain Tumor Drugs Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the brain tumor drugs market in 2025. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
